Compare Merck & Co., Inc. (MRK) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Symbotic Inc — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Symbotic Inc trades at $42.9 (market cap $5.62B). The key difference: Merck & Co., Inc. is far larger — about 65.2× Symbotic Inc's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| MRK | SYM | |
|---|---|---|
Market Cap | $366.28B | $5.62B |
Sector | Health | Technology |
52-Week High | $156.43 | $87.30 |
52-Week Low | $77.60 | $38.22 |
Enterprise Value | $413.04B | $3.88B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
SYM trades at $43.30, up 0.84% today, with a bullish technical signal from moving averages and ADX indicators. The company reported revenue of $2.25B in 2025 but posted a net loss of $16.94M, though 2026 projections show potential profitability. Analyst consensus is bullish with a $56.50 price target, representing 30% upside potential from current levels. Recent news highlights Symbotic's $22.5B backlog and strategic partnership with Stanford Robotics Center.
SYM presents growth potential with strong revenue projections and massive backlog, but faces risks from customer concentration (85% revenue from Walmart) and recent earnings misses. The stock appears undervalued with a P/E of 1,082.5, though negative EBITDA and thin margins warrant caution. Institutional interest remains positive with new investments, but insider selling and legal investigations create near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
